Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Feb;37(1):95-105.
doi: 10.1007/s10585-019-10006-1. Epub 2019 Nov 15.

Quality of life in patients with liver tumors treated with holmium-166 radioembolization

Caren van Roekel  1 , Maarten L J Smits  2 , Jip F Prince  2 , Rutger C G Bruijnen  2 , Maurice A A J van den Bosch  2 , Marnix G E H Lam  2
Affiliations
Clinical Trial

Quality of life in patients with liver tumors treated with holmium-166 radioembolization

Caren van Roekel et al. Clin Exp Metastasis. 2020 Feb.

Abstract

Holmium-166 radioembolization is a palliative treatment option for patients with unresectable hepatic malignancies. Its influence on quality of life has not been evaluated yet. Since quality of life is very important in the final stages of disease, the aim of this study was to evaluate the effect of holmium-166 radioembolization on quality of life. Patients with hepatic malignancies were treated with holmium-166 radioembolization in the HEPAR I and II studies. The European Organization for Research and Treatment of Cancer QLQ-C30 and LMC21 questionnaires were used to evaluate quality of life at baseline, 1 week, 6 weeks and at 6, 9 and 12 months after treatment. The course of the global health status and symptom and functioning scales were analyzed using a linear mixed model. Quality of life was studied in a total of 53 patients with a compliance of 94%. Role functioning was the most affected functioning scale. Fatigue and pain were the most affected symptom scales. Changes in almost all categories were most notable at 1 week after treatment. A higher WHO performance score at baseline decreased global health status, physical functioning, role functioning and social functioning and it increased symptoms of fatigue, dyspnea and diarrhea. Quality of life in salvage patients with liver metastases treated with holmium-166 radioembolization was not significantly affected over time, although a striking decline was seen during the first week post-treatment. A WHO performance score > 0 at baseline significantly influenced quality of life.

Keywords: Hepatic metastases; Holmium-166; Quality of life; Radioembolization.

PubMed Disclaimer

Conflict of interest statement

M.G.E.H. Lam is a consultant for BTG and Terumo. M.L.J. Smits has served as a speaker for Sirtex and Terumo.

Figures

Fig. 1
Fig. 1
Median global health score over time with interquartile range (shaded area). A high score represents a good health score
Fig. 2
Fig. 2
Median role functioning scores over time with interquartile ranges (shaded areas). BL baseline, 1w 1 week, 6w 6 weeks, 3 m 3 months, 6 m 6 months, 9 m 9 months, 12 m 12 months. A high score represents good functioning
Fig. 3
Fig. 3
Global health status in patients with different WHO performance scores. The black lines depict the development of GHS per patient. The blue lines with shaded area represent the geometric mean with standard deviation. BL baseline, 1w 1 week, 6w 6 weeks, 3 m 3 months, 6 m 6 months, 9 m 9 months, 12 m 12 months. (Color figure online)
See this image and copyright information in PMC

References

    1. Townsend AR, Chong LC, Karapetis C, Price TJ. Selective internal radiation therapy for liver metastases from colorectal cancer. Cancer Treat Rev. 2016;50:148–154. doi: 10.1016/j.ctrv.2016.09.007. - DOI - PubMed
    1. Smits ML, Elschot M, van den Bosch MA, van de Maat GH, van het Schip AD, Zonnenberg BA, Seevinck PR, Verkooijen HM, Bakker CJ, de Jong HW, Lam MG, Nijsen JF. In vivo dosimetry based on SPECT and MR imaging of 166Ho-microspheres for treatment of liver malignancies. J Nucl Med. 2013;54(12):2093–2100. doi: 10.2967/jnumed.113.119768. - DOI - PubMed
    1. Braat AJ, Smits ML, Braat MN, van den Hoven AF, Prince JF, de Jong HW, van den Bosch MA, Lam MG. (9)(0)Y hepatic radioembolization: an update on current practice and recent developments. J Nucl Med. 2015;56(7):1079–1087. doi: 10.2967/jnumed.115.157446. - DOI - PubMed
    1. Riaz A, Awais R, Salem R. Side effects of yttrium-90 radioembolization. Front Oncol. 2014;4:198. doi: 10.3389/fonc.2014.00198. - DOI - PMC - PubMed
    1. Tominaga T, Nonaka T, Sumida Y, Hidaka S, Sawai T, Nagayasu T. The C-reactive protein to albumin ratio as a predictor of severe side effects of adjuvant chemotherapy in stage III colorectal cancer patients. PLoS ONE. 2016;11(12):e0167967. doi: 10.1371/journal.pone.0167967. - DOI - PMC - PubMed

Publication types

MeSH terms